Basics Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases. IPO Date: October 23, 2013 Sector: Healthcare Industry: Biotech Market Cap: $587.72M Activated in VL: True Average Daily Range Avg Daily Range: $0.48 | 3.12% Avg Daily Range (30 D): $0.10 | 4.35% Avg Daily Range (90 D): $0.12 | 3.71% Institutional Daily Volume Avg Daily Volume: 3.08M Avg Daily Volume (30 D): 14.4M Avg Daily Volume (90 D): 10.78M Trade Size Avg Trade Size (Sh.): 149 Avg Trade Size (Sh.) (30 D): 448 Avg Trade Size (Sh.) (90 D): 315 Institutional Trades Total Inst.Trades: 5,198 Avg Inst. Trade: $2.56M Avg Inst. Trade (30 D): $2.04M Avg Inst. Trade (90 D): $2.02M Avg Inst. Trade Volume: .21M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.12M Avg Closing Trade (30 D): $1.98M Avg Closing Trade (90 D): $2.57M Avg Closing Volume: 354.81K     News Jun 8, 2025 @ 12:18 PM IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. ... Source: N/A Jun 5, 2025 @ 2:15 AM IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSF... Source: Claimsfiler Jun 4, 2025 @ 8:57 PM Iovance’s (IOVA) Promising Cell Therapy Fal... Source: Hagens Berman Jun 4, 2025 @ 4:00 PM DEADLINE ALERT for IOVA, DNUT, MSTR, DV: Law Offic... Source: Law Offices Of Howard G. Smith Jun 4, 2025 @ 2:46 AM IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORME... Source: Kahn Swick & Foti, Llc Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.36 $-.28 Diluted EPS $-.36 $-.28 Revenue $ $ 49.32M $ 58.56M Gross Profit $ $ -.42M $ 18.73M Net Income / Loss $ $ -116.16M $ -83.54M Operating Income / Loss $ $ -121.22M $ -89.07M Cost of Revenue $ $ 49.74M $ 39.82M Net Cash Flow $ $ 56M $ -64.57M PE Ratio     Splits Sep 26, 2013:   1:100 Apr 06, 2010:   24:1